Pediatrix Medical Group
MDNYSEUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $31.62 Prior regular-session close from the quote source.
- $30.24–$31.48 Regular-session low and high so far today.
- 930.9K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Feb 18 projected Projected for 2027-02-18 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $17.23–$33.74 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own MD if the 2025 profit rebound proves durable rather than a one-year recovery in a pressured staffing model.
MD price history
Loading recent earnings…
Investment thesis
What must happen next
Hospitals continue to rely on Pediatrix for outsourced newborn, maternal-fetal, and pediatric subspecialty coverage because specialized staffing and call coverage are hard to replicate in-house.HoldingMateriality: High
Item 1 profile description identifies Pediatrix as a leading provider of physician services including newborn, maternal-fetal, and other pediatric subspecialty care. If this holds, Pediatrix keeps a resilient revenue base; if hospitals insource or switch providers, the platform loses its core demand anchor.
Watch: Large hospital systems begin insourcing neonatal intensive care, maternal-fetal medicine, or pediatric subspecialty programs instead of contracting with Pediatrix.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Item 1 profile description identifies Pediatrix as a leading provider of physician services including newborn, maternal-fetal, and other pediatric subspecialty.
Open source ↗Pediatrix can reprice, renegotiate, or rationalize weak contracts quickly enough that reimbursement and hospital-support economics outrun clinician wage pressure.StrengtheningMateriality: High
GAAP annual operating income recovered to $208.813 million in FY2025 from a GAAP operating loss of $68.713 million in FY2024. This is the difference between a stable service provider and a low-margin staffing business whose scale does not protect owners.
Watch: Physician and advanced-practitioner wage inflation accelerates faster than Pediatrix can pass through to hospitals or payers.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating income recovered to $208.813 million in FY2025 from a GAAP operating loss of $68.713 million in FY2024.
Open source ↗The physician-services model remains asset-light enough that repaired contract economics convert into operating cash flow rather than being consumed by facility investment.StrengtheningMateriality: Medium
GAAP annual operating cash flow was positive in each available year from FY2022 through FY2025. Durable cash conversion gives owners real value creation; weak cash conversion would imply accounting earnings are not translating into economic returns.
Watch: Payer denials, delayed collections, or No Surprises Act dispute processes materially extend receivable cycles.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow was positive in each available year from FY2022 through FY2025.
Open source ↗Management preserves balance-sheet flexibility so reimbursement, legal, or labor shocks do not force value-destructive capital raising or distressed contract decisions.StrengtheningMateriality: Medium
Cash and cash equivalents increased to $375.241 million at FY2025 year-end from $229.940 million at FY2024 year-end. A stronger cash cushion lets Pediatrix absorb volatility and negotiate from strength; a weakened balance sheet would transfer value from equity owners to creditors or counterparties.
Watch: Management pursues leverage-increasing acquisitions before the operating recovery is proven durable.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash and cash equivalents increased to $375.241 million at FY2025 year-end from $229.940 million at FY2024 year-end.
Open source ↗The FY2025 per-share recovery must reflect durable operating repair rather than one-time accounting benefits, temporary cost relief, or reserve reversals.HoldingMateriality: Medium
GAAP diluted EPS improved to $1.94 in FY2025 from a GAAP diluted loss of $1.19 in FY2024. If the EPS rebound is sustainable, equity value can compound; if it is one-time, owners risk capitalizing peak earnings.
Watch: Future filings show FY2025 earnings were driven by nonrecurring gains, reserve releases, or unusually favorable tax/accounting items.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP diluted EPS improved to $1.94 in FY2025 from a GAAP diluted loss of $1.19 in FY2024.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Hospitals continue to rely on Pediatrix for outsourced newborn, maternal-fetal, and pediatric subspecialty coverage because specialized staffing and call coverage are hard to replicate in-house. If this holds, Pediatrix keeps a resilient revenue base; if hospitals insource or switch providers, the platform loses its core demand anchor.
Pediatrix can reprice, renegotiate, or rationalize weak contracts quickly enough that reimbursement and hospital-support economics outrun clinician wage pressure. This is the difference between a stable service provider and a low-margin staffing business whose scale does not protect owners.
The physician-services model remains asset-light enough that repaired contract economics convert into operating cash flow rather than being consumed by facility investment. Durable cash conversion gives owners real value creation; weak cash conversion would imply accounting earnings are not translating into economic returns.
Management preserves balance-sheet flexibility so reimbursement, legal, or labor shocks do not force value-destructive capital raising or distressed contract decisions. A stronger cash cushion lets Pediatrix absorb volatility and negotiate from strength; a weakened balance sheet would transfer value from equity owners to creditors or counterparties.
The FY2025 per-share recovery must reflect durable operating repair rather than one-time accounting benefits, temporary cost relief, or reserve reversals. If the EPS rebound is sustainable, equity value can compound; if it is one-time, owners risk capitalizing peak earnings.
All standing thesis claims
Original report summary
the 2025 profit rebound proves durable rather than a one-year recovery in a pressured staffing model.
Bull case and bear case
Bull case and bear case for Pediatrix Medical Group
Where the evidence on Pediatrix Medical Group stands: Holding on the latest evidence (Oct 16, 2026). Of its 5 thesis points, 3 strengthening and 2 holding.
Bull case: what the evidence supports
Hospitals continue to rely on Pediatrix for outsourced newborn, maternal-fetal, and pediatric subspecialty coverage because specialized staffing and call coverage are hard to replicate in-house.
Pediatrix can reprice, renegotiate, or rationalize weak contracts quickly enough that reimbursement and hospital-support economics outrun clinician wage pressure.
The physician-services model remains asset-light enough that repaired contract economics convert into operating cash flow rather than being consumed by facility investment.
Management preserves balance-sheet flexibility so reimbursement, legal, or labor shocks do not force value-destructive capital raising or distressed contract decisions.
The FY2025 per-share recovery must reflect durable operating repair rather than one-time accounting benefits, temporary cost relief, or reserve reversals.
Bear case: what would count against it
Large hospital systems begin insourcing neonatal intensive care, maternal-fetal medicine, or pediatric subspecialty programs instead of contracting with Pediatrix.
Physician and advanced-practitioner wage inflation accelerates faster than Pediatrix can pass through to hospitals or payers.
Payer denials, delayed collections, or No Surprises Act dispute processes materially extend receivable cycles.
Thesis-Break Engine
Thesis-break watch · Pediatrix Medical Group
Loading the break-condition record for Pediatrix Medical Group.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
Pediatrix Medical Group filed an SEC 8-K on 2026-08-04: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
Pediatrix Medical Group filed an SEC 8-K on 2026-07-24: Director or principal officer change. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Pediatrix Medical Group filed an SEC 8-K on 2026-07-15: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Large hospital systems begin insourcing neonatal intensive care, maternal-fetal medicine, or pediatric subspecialty programs instead of contracting with Pediatrix.
- Physician and advanced-practitioner wage inflation accelerates faster than Pediatrix can pass through to hospitals or payers.
- Payer denials, delayed collections, or No Surprises Act dispute processes materially extend receivable cycles.
- Management pursues leverage-increasing acquisitions before the operating recovery is proven durable.
- Future filings show FY2025 earnings were driven by nonrecurring gains, reserve releases, or unusually favorable tax/accounting items.
MD news
Loading headlines…
Financial statements
MD income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
MD: quick answers
- When does Pediatrix Medical Group (MD) report earnings next?
- Pediatrix Medical Group's next results are projected for February 18, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on October 29, 2026. Earnings calendar
- What is MD's short interest?
- As of October 30, 2026, 3.5M MD shares were sold short, 4.54% of its shares outstanding, down 18.9% from the count before. At the stock's average daily volume that is 5.0 days to cover. FINRA publishes the count twice a month. MD short interest history
- Have members of Congress traded MD?
- 10 trades in MD have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed MD trade